Skip to main content

Jamaica’s Trade Minister: U.S. Cannabis Banking Reform Is Desperately Needed

Jamaica has a long history when it comes to cannabis. The cannabis plant is ingrained in the island nation’s culture, and thanks to cannabis reform efforts, it’s preparing to take its rightful place as an international cannabis industry leader.

The Carribean country is working to finalize rules and regulations for cannabis exports, with its sights set on lucrative international markets such as Germany and Australia. Jamaica’s Trade Minister Audley Shaw stated this week that there’s a major roadblock in the way right now – cannabis prohibition in the United States, and more specifically, banking issues related to the U.S. prohibition policy. Per Bloomberg:

“It’s really a roadblock, no other word for it, it’s a major roadblock in the advancement of medicinal cannabis,” Shaw said in an interview at Bloomberg’s New York office Wednesday.

He’s particularly passionate about marijuana’s potential to reduce opioid addiction rates, and is hoping to bring his message all the way to President Donald Trump.

“The gravity of this situation requires the highest level of focus,” he said.

Minister Shaw went on to point out the blatant hypocrisy of the United States allowing Canadian cannabis companies to list on its stock exchanges yet at the same time prohibiting United States cannabis companies from being able to do the same thing.

Shaw also pointed out that it’s ridiculous that there are serious hurdles for cannabis banking in his country due to U.S. policy while at the same time Canadian cannabis companies are able to offer stock options in the U.S.

Jamaica is not the only country experiencing banking issues due to the current United States cannabis policy. Uruguay has also reportedly experienced issues. The SAFE Banking Act was already approved by the United States House of Representatives. Hopefully the legislation passes soon in the U.S. Senate and is signed into law for the sake of the emerging cannabis industry in the U.S., Jamaica, and elsewhere.

Canadian Cannabis Company Aims To Undercut Unregulated Market Prices

One of the biggest benefits of legalizing and regulating cannabis sales is taking revenue away from the unregulated cannabis market. An unregulated cannabis market is never entirely operated by gangs and cartels, however, it is well documented that gangs and cartels do use illegal cannabis sales in some cases to help generate revenue.

Rather than having consumer dollars supporting those types of entities, it is much better for consumer dollars to support a regulated system in which revenue is generated by licensed entrepreneurs, some of which goes to taxes that support society. It is better for local economies and it is ultimately better for consumers who are able to purchase tested products that have met industry safety standards.

Convincing consumers to make their purchases through a regulated system is easier said than done. A number of factors affect consumer purchasing practices, with arguably the biggest factor being the cost of the cannabis to the end consumer.

Regulated options provide a number of non-monetary benefits including variety and convenience. However, those benefits only go so far. If regulated cannabis is significantly more expensive than unregulated cannabis, consumers will often make their purchases through unregulated sources.

A Canadian cannabis company has announced that it is going to offer a cannabis flower option that will cost less than the average price of cannabis flower from unregulated cannabis dispensaries. Per Global News:

Cannabis company Hexo Corp. says it is aiming to undercut prices in the illicit market with its new 28-gram product, that costs as much as one dollar less per gram than at a illegal dispensary.

Hexo says the product will be on sale in Quebec cannabis stores for $125.70 taxes included, or $4.49 per gram.

Statistics Canada’s latest price analysis based on crowdsourced data showed that the average cost of a gram of cannabis was $7.37 during the third quarter, with the price of legal and illegal weed slipping to $10.23 and $5.59 per gram, respectively.

The cannabis flower will be sold under the name ‘Original Stash’ and will have a THC content between the range of 12% and 18%. The THC percentage could be an issue and affect the potential success of the new offering. Many cannabis consumers prefer cannabis flower that tests at 20% or above.

The proposed price for the 28 grams of Original Stash could also be an issue too. $4.49 per gram may be lower than the average price of a gram at an unregulated dispensary in Canada, but it’s likely not lower than a non-dispensary gram of flower. Consumers may still be able to find cannabis for cheaper from a local dealer and continue to opt to make purchases from them.

With that being said, the lower price should still cut into unregulated cannabis sales to some extent. How much of an impact it will ultimately have is something that will be determined in the coming months as sales data is compiled and analyzed.

Zimbabwe Makes History With Planting Of First Legal Hemp Crop

Zimbabwe may not be the first place that people think of when they think of hemp, however, the African nation made history this month when it planted its first crop of hemp. Zimbabwe legalized the production of hemp last year for medical and scientific purposes and legalized hemp for industrial purposes in September of this year.

The Zimbabwe Industrial Hemp Trust (ZIHT) planted six different varieties of hemp. ZIHT was the first entity to receive a hemp cultivation license in Zimbabwe’s history. The license is valid for 5 years. It was a monumental development for Zimbabwe, as Zimbabwe’s Agricultural Minister pointed out according to Yahoo News:

“This project is the first of its kind in the history of our country,” Agriculture Minister Perence Shiri told guests at the launch in Harare central prison.

“This pilot project will provide essential knowledge or information for the successful production of this crop. The benefits that will be derived from the production of industrial hemp are enormous and varied,” he said.

The location of the historic hemp garden is significant in multiple ways. The fact that it used to be a prison is representative of both hemp prohibition’s past in Zimbabwe as well as how much times are changing on the African continent and around the world.

ZIHT has stated that it chose the site because security features were already built into the property, which makes sense. It’s not the first former correctional facility to be converted into a cannabis cultivation facility. Similar types of facilities in North America have been converted over the years.

However, this is the first time that the conversion of a prison facility has been doubled with it also simultaneously being the location of the first legal planting in a nation’s history, and that’s definitely worth celebrating.

What Is Canadian Cannabis Legalization 2.0?

Roughly a year ago Canada became the first G-7 nation to legalize cannabis for adult-use. Canada rolled out a regulated adult-use cannabis industry in a limited fashion last October. Canada’s model was built around cannabis flower sales, which will be changing soon.

In just a handful of weeks cannabis edibles, vape products, beverages, and other items will hit regulated cannabis store shelves in Canada. The delayed implementation is a result of Canadian lawmakers and regulators needing more time to come up with regulations for cannabis beyond just flower sales.

By mid-December, the new products will go on sale in Canada which is going to be a really big milestone for Canada’s cannabis industry. The historic launch is being dubbed ‘cannabis 2.0’ in media coverage around the globe. Cannabis 2.0 is expected to provide a significant boost to Canada’s economy. Per Financial Post:

The introduction of extracts is estimated to add an additional $2.7 billion to the cannabis market, according to Deloitte, but as producers add dozens of new products, retailers may already be facing a crunch in terms of how much of it they can actually carry.

Cannabis 2.0 will help address the ongoing issue of consumers continuing to purchase cannabis products from Canada’s unregulated market. Consumers want more options than just cannabis flower. The unregulated industry will never be eliminated in Canada, however, many consumers prefer to purchase cannabis from regulated sources as long as the prices are reasonable. Hopefully that proves to be the case in Canada.

Price points and shelf access are going to be two really big determining factors as to whether cannabis 2.0 is successful or misses the mark. If cannabis edibles and other new products are expensive and hard to find, it will obviously result in consumers continuing to turn to unregulated sources.

Which State Will Be The First To Legally Import/Export Cannabis In The U.S.?

Importing and exporting cannabis illegally between states is not a new thing in the U.S. Far from it. Ever since cannabis was federally prohibited in the 1930’s illegal cannabis sales have occurred in the U.S. with much of the cannabis involved having crossed one or more state borders along the way before making it to the end consumer.

Oregon lawmakers made history this year when they passed the first-ever cannabis import/export bill (not including hemp). The Craft Cannabis Alliance was instrumental in getting the bill passed and educating Oregon lawmakers on the benefits of cannabis import/export reform. The organization’s Founder and Director, Adam J. Smith, recently published an in-depth article about why other states need to be allowed to adopt measures similar to what Oregon’s Legislature passed in 2019. The article is a must-read.

The cannabis oversupply situation in Oregon was covered by mainstream media outlets numerous times in recent years. A lot of the media hysteria and hype is unwarranted considering that a significant amount of the oversupply is no longer usable and is simply lingering in Oregon’s seed-to-sale tracking system. However, that’s not to say that the recently passed reform measure was not needed.

Cannabis is an agriculture crop. it will likely always be regulated differently than tomatoes, but it’s ultimately a crop. Virtually all legal crops are imported and exported in some fashion between states. Demand for cannabis is very strong nationwide, so it is only logical to expect that at some point there will be a regulated system to help supply meet demand via interstate cannabis commerce.

A handful of states are exploring the idea of following in Oregon’s footsteps. Many cannabis observers are asking each other ‘when will the first legal cannabis import/export actually happen? When it does happen, which states will be involved?’

I have stated previously that I expect Oregon and Nevada to be the first states involved, with Oregon exporting sungrown cannabis to Nevada. That is still my prediction. For starters, Oregon is ready to enter into an interstate agreement right now, pending federal permission from the U.S. Department of Justice or via an act of Congress.

Nevada shares a border with Oregon and has allowed legal adult-use cannabis sales for awhile. Some cannabis observers have pointed out, and understandably so, that Nevada’s industry cultivates its own cannabis and so, therefore, its industry (and policymakers) would likely oppose allowing imports, and adamantly at that.

It’s a very valid point, however, it doesn’t take one important factor into account. Cannabis consumers want to make purchases, and if there is no supply at regulated outlets to make a purchase due to a shortage, they will turn to other sources, including the unregulated market which still exists and likely always will exist in Nevada.

Even if a consumer doesn’t turn to the unregulated market, they would immediately go to a competitor to purchase cannabis if their preferred outlet is out of stock or charging higher prices due to a shortage. As a desert state, Nevada’s climate is not ideal for cultivating quality cannabis under the sun, and that could be problematic over time.

A series of setbacks among large cultivators in Nevada could easily result in a situation where cannabis is in short supply, similar to what is currently going on in parts of Colorado, or occurred in California after large wildfires destroyed huge cannabis farms. The demand for cannabis in the state of Nevada will remain constant if/when a shortage happens. What will the state do to help fill the void?

Entrepreneurs, regulators, and even lawmakers have a vested interest in keeping Nevada’s legal cannabis industry humming along in order to keep consumers from turning to the unregulated market. Importing cannabis legally from another state is a logical solution to the problem if/when it happens, and Oregon is the perfect partner to help fill the void if that ever proves to be the case in Nevada.

A policy allowing Nevada to import legal cannabis from Oregon would not necessarily be designed to replace Nevada’s cannabis cultivation sector. Rather, it would be geared towards helping supplement it. In some instances, it may make more financial sense to import cannabis from Oregon to the Nevada market. After all, Oregon’s cultivation community is capable of producing a tremendous amount of world-class cannabis at likely a cheaper price than any other state.

However, many consumers would still likely prefer to buy locally-sourced cannabis. After the local sources run out, entrepreneurs would then turn to Oregon to help fill the void to keep the supply steady. Eventually, most states will have cannabis from a laundry list of other states on regulated shelves in their jurisdictions, just as they do a number of other consumables (including alcohol). Yet, before that happens, two states will have to be the first to put things in motion.

That could happen even prior to federal permission being granted. After all, it wouldn’t be the first time that Oregon and Nevada defied federal cannabis law. It’s not likely, but it’s certainly not a far-fetched concept either.

One wild-card scenario is worth touching on in this discussion. A way that I can see cannabis imports/exports occurring in a scenario that doesn’t involve Oregon or Nevada could possibly be via a social-equity multi-state program. This type of public policy concept would involve social-equity cultivation licensees in one state exporting their cannabis to social-equity licensees in another state.

When a state initially passes a reform measure creating a legal cannabis industry, it takes quite a bit of time for cannabis companies to go from obtaining a license and starting a cannabis cultivation facility all the way to actually selling products to the end consumer. In states with no regulatory framework in place, that process could take years.

With enormous startup costs and the length of time involved until a sale is made in the scenario described, many would-be cannabis entrepreneurs simply wouldn’t have the resources to get involved in the cannabis industry in a meaningful way. That is especially true for members of communities disproportionately affected by cannabis prohibition.

State-to-state equity programs would not only help mitigate the issues described, but it would also give social-equity licensees a significant headstart over people and entities with huge resources, which is something that the cannabis industry, regulators, and lawmakers everywhere should all be embracing. I would personally love to see it happen.

For the time being though, it seems like other states are unlikely to beat Oregon and Nevada to the punch. If that did happen, it would take a perfect storm. Nevada is home to a huge demand for cannabis in a desert climate, and Oregon has the ability to cultivate world-class cannabis on the other side of the state border. Oregon also already has a policy in place (albeit without the regulations). That scenario does not exist anywhere else in the United States right now.

California is another likely candidate to help fill any potential supply voids in Nevada. After all, California can also cultivate world-class cannabis and also shares a border with Nevada. However, Oregon is much farther along on the policy side, and California is still working on addressing its own intrastate commerce hurdles and issues, so I think a California-to-Nevada scenario is far less likely to occur than an Oregon-to-Nevada scenario.

Former Health Canada Inspector Dr. Sherry Boodram Joins Nextleaf Solutions Board Of Directors

Nextleaf Solutions, a leading cannabis extraction technology company, has announced today that it has added Dr. Sherry Boodram, former Senior Regulatory Compliance Officer with Health Canada, to its Board of Directors, effective immediately.

Dr. Sherry Boodram worked for the Canadian federal government for several years and was responsible for licensing application reviews and on-site facility inspections of Canadian cannabis industry facilities.

Dr. Boodram also provided field level input during the drafting of the current Canadian cannabis regulations.

“Being a company with values I can stand behind, I’m very excited to serve alongside Nextleaf’s existing Board members and with their talented executive team,” stated Dr. Sherry Boodram. “Moreover, I look forward to maximizing the unique knowledge and experience I gained while at Health Canada’s Medical Cannabis Program, and in the cannabis industry as a whole, to provide expertise in support of Nextleaf’s ongoing commitment to regulatory compliance, good governance, and long-term growth as a leader in cannabis extraction technology.”

Dr. Boodram holds a Ph.D. in Chemistry from York University, a B.Sc. (Hon) from the University of Toronto, and a Graduate Certificate with Honours in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College. Dr. Boodram is also a member of the Canadian Association of Professionals in Regulatory Affairs (CAPRA).

Currently, Dr. Boodram is the co-founder and CEO of CannDelta Inc. (“CannDelta”) – a regulatory and scientific cannabis consulting company based out of Toronto, Canada – where she provides regulatory expertise and develops strategies to ensure regulatory compliance within Canada’s existing legal cannabis framework.

“The serious regulatory infractions by several large Canadian licensed cannabis producers, along with an expanded scope of cannabis products through legalization 2.0, reinforces the critical role that compliance oversight plays in building a cannabis company all stakeholders can be proud of,” stated Paul Pedersen, co-founder and CEO of Nextleaf Solutions. “Sherry is amongst the most credible and qualified cannabis regulatory experts in Canada, and we believe her background, insights, and industry experience will add tremendous value to our Board.”

About Nextleaf Solutions

Nextleaf Solutions Ltd. (“OILS”) is developing disruptive intellectual property for industrial-scale extraction, purification, and formulation of cannabinoids. OILS owns a portfolio of eight (8) issued and 35 pending patents pertaining to the production of high-purity, cannabinoid-rich distillate, the key ingredient used in the manufacturing of standardized THC and CBD infused products. Once cannabis concentrates and edibles become legal across Canada, OILS plans to commercialize its intellectual property portfolio through IP licensing, B2B processing services, and the supply of THC and CBD oils and concentrates to qualified Canadian and international partners.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange (CSE: OILS), OILFF on the OTCQB Market in the United States (OTCQB: OILFF) and L0MA on the Frankfurt Stock Exchange (FSE: L0MA).

For more information visit www.nextleafsolutions.com or follow OILS across social media platforms: Twitter, LinkedIn, Facebook, and Instagram.

Would A Successful Brexit Boost The Chances Of British Cannabis Legalization?

It is no secret that the British are in a bit of a constitutional pickle at the moment. How far the country will align itself with the US and outside of the EU is still in play, two weeks out from Halloween. 

One of the stranger vibes in the air, especially after Boris Johnson hired two cannabis reform advocates into his office of late, is the idea that chucking the relationship with the EU and recreational cannabis reform might be linked, if not a good clarion call. 

After all, Aron Banks is no stranger to the CBD call either.

Are people on the British side of the industry seriously advocating Brexit as a way to push forward recreational cannabis reform in the UK? The answer, shockingly, appears to be yes.

Burn It All Down, Baby

For those at the pointed end of the cannabis discussion (namely patients), the debate about how money laundering laws are enforced to target cannabis-themed investments or not within the UK is currently a bit of a cruel joke. For anyone invested or working in the cannabis industry, the continued stutters and starts of the British market is not part of an academic discussion. 

Also, the snail’s pace of British cannabis reform has continued to prove to be too much for just about everyone. 

Who Can Blame The Brits For Wanting Their (Medical) Spice Cake And Eating It Too?

In this environment, it is tempting to just push recreational cannabis reform ideas under the larger ideas of burn, baby, burn which seems to now be in fashion in the geography of Number 10 (Downing Street and official residence of the British Prime Minister).

However, for those who think Brexit is a quick fix – think again.

Start with the fact that the UK is an island nation, and would be required to suddenly grow and source a huge amount of its own food and medicine. Also, the NHS would, as most believe now, simply not survive. Private (American-style) healthcare anyone?

While cannabis might in such circumstances come to be lauded as the wonder drug it is, like a new penicillin for example, does anyone think that bouncing the British economy around to do it under this kind of turbulence is really in the best interests of either patients or recreational consumers that would presumably be shell and wallet shocked?

Deregulation, in other words, and certainly of the kind that seems still to be in the room with a no-deal Brexit, might seem exciting, particularly to those frustrated with the hangover of the prohibition of the past.

However, such strategies are indeed a double-edged sword, both for (certainly) the British economy as well as Britain’s most vulnerable citizens who are cannabis users either “by choice” or through necessity.

How Might European Tax Credits Help Finance The Cannabis Industry?

For all of the hurdles that exist in the European market, there is one avenue that has, so far at least, remained remarkably unexplored. That is certainly the case on the financing end.

Yes, European family offices are conservative, and “equity” (at least as it is thought of in the North American sense) remains less interesting in the free for all of public markets among Europeans compared to their cross Atlantic peers.

However, for the right canna-entrepreneur, the most attractive thing about European financing so far has remained largely off the table. Namely tax credits, especially of the R&D and tech kind (although there are other kinds of credits on the table when crossing into related fields.)

Yes, there are rules about this kind of thing (and a lot of regulations). But as a vehicle for helping to offset the risk of evolving medical cannabis projects in particular, the pursuit of obtaining these tax credits has so far remained in its infancy.

It won’t for long. 

Where, Why and How Will This Impact Industry Growth?

For an industry that so far has financed its highest fliers via the public equity markets (and exotic financial instruments like reverse mergers), the European financing options now on the table are intriguing, if not much more attractively legit. 

Tax credits have already shown up of course. The largest firms from Canada are hip to this game. But increasingly so are the smaller players, and that is where tax credits and other financial instruments and structures here will start to play a bigger difference.

Writing off the construction of a GMP facility may not be entirely “experimental,” yet putting a new drug into it certainly could qualify. That’s especially true with any kind of qualifying research attached.

Right now, that is a siren’s song to a green industry that has frequently been short of cash.

Who Can Use This Kind Of Financing?

The best thing about tax credits is that they operate as a kind of insurance for investors looking for some way to offset the risk of investing in a new market. Cover the investment with a multi-year tax credit just in case? That is, for those who have a need for such vehicles, a no-lose proposition.

The only catch is that entrepreneurs need the right team (experts, including lawyers, and financiers are a must.) This is not something you do at home, or by yourself.

For the latest in Euro-financing strategies, be sure to attend the International Cannabis Business Conference 2020 in Europe in Barcelona, Berlin and Bern!

Demecan’s Successful Series A Financing Round Is A Major Milestone For Germany’s Domestic Cannabis Industry

Germany’s medical cannabis industry is increasing in size with every passing quarter. The profit potential for the nation’s emerging medical cannabis industry is significant considering that Germany is home to the largest economy in Europe and has more than twice the population of California.

For obvious reasons, Germany has been a very popular target for cannabis exports from other countries, including exports from Canada, Australia, Colombia, Portugal, and Uruguay.

Only one German-based company has permission to cultivate medical cannabis domestically. That company is Demecan. The Berlin startup recently completed a Series A financing round in which it raised €7 million to expand its ability to produce wholesale cannabis for the German medical cannabis market.

Demecan is expected to use the financing to ramp up cultivation, with an estimated output of at least 2,400 kilograms of dried cannabis flower over the course of the next four years.

Demecan may not be 100% German-owned (Canada’s Wayland Group owns 50% of Demecan), however, the recent financing is still very significant because it will help increase the amount of domestically cultivated cannabis in Germany in a way that results in wholesale revenues staying in Germany.

The German medical cannabis market possesses tremendous profit potential, yet it’s extremely important to keep in mind that revenues will be split up into various slices. As the slice for German-owned companies gets larger the slice for everyone else obviously becomes smaller.

Investors and entrepreneurs will have to adjust their strategies accordingly. That’s not to say that they should abandon efforts to gain market share in Germany altogether, because after all, the German medical cannabis industry is going to be huge.

However, it’s absolutely worth keeping a close eye on the situation to see how successful domestic production ultimately becomes in Germany. 

Domestic cultivation could prove to be more advantageous for various reasons compared to importing cannabis. One of the biggest reasons why is that domestic cannabis, and products derived from domestically cultivated cannabis, could prove to be considerably more popular among patients.

The demand for cannabis in Germany is going to continue to increase well into the foreseeable future. Recent data regarding reimbursements by statutory health insurers in German shows that for the April-June 2019 period sales reached roughly 29.5 million euros – a 20% increase over the previous quarter. That upward trend will continue.

Germany is currently the largest importer of cannabis on the planet. As domestically cultivated cannabis makes its way into the German medical cannabis market, it will have a big impact on the international cannabis industry.

International cannabis companies have been awarded licenses to cultivate medical cannabis within Germany’s borders, so it’s not as if German-based cannabis companies have a monopoly on cultivation.

However, Demecan’s successful series A financing round is still a huge milestone for the emerging German medical cannabis industry. Reliance on imports could reduce significantly in the coming years.

If Demecan puts their new funding to good use, and its domestic cannabis cultivation model succeeds in Germany, more funds will likely be on the way. That could have a butterfly effect on plans by international companies, with those companies scaling back their plans in Germany.

The domestic cultivation model could also be adopted elsewhere in Europe if Demecan is successful going forward, which would impact additional pursuits of international companies throughout the continent.

Of course, if Demecan fails to meet expectations due to a multitude of potential factors, that could result in other governments and investors opting to support industry models that are more reliant on imports.

A lack of supply is something that patients, lawmakers, and regulators in Germany want to avoid. That will also be true in other European countries as they ramp up their industries. 

The supply for Germany’s medical cannabis industry will obviously come from somewhere, the question that will ultimately be answered by the passing of time is what amount of that supply will originate from domestic sources versus what amount will be imported?

The success or failure of Demecan will have a big impact on what opportunities will be available in Germany in the coming years, and possibly in other countries. 

The Demecan situation will result in winners and losers. Which side of the equation will those winners and losers fall on? We will all have to wait and see. In the meantime, keep a close eye on the matter as it develops in order to make informed investment decisions in Germany and beyond.